1. Show article details.

    Momentum Indicators for Health Care Equities -- Research on ResMed, CareFusion, DENTSPLY Intl., and DexCom

    PR Newswire – 12:42 PM ET 03/26/2014

    LONDON, March 26, 2014 The trading session on Tuesday, March 25, 2014 ended on a higher note as the Dow Jones Industrial Average finished at 16,367.88, up 0.56% and the NASDAQ Composite closed at 4,234.27, up 0.19%. The S&P 500 finished the session 0.44% higher at 1,865.62. The gains were broad based as nine out of ten sectors ended the session in positive. SOURCE Investor-Edge.

  2. Show article details.

    DexCom Receives FDA Warning Letter for Administrative Deficiencies in its MDR Reporting

    Business Wire – 8:30 AM ET 03/25/2014

    DexCom, Inc. (DXCM) announced today that it has received a warning letter from the U.S. Food & Drug Administration resulting from a November 2013 inspection of the Company’s facility in San Diego, California by the FDA’s Los Angeles District Office.

  3. Show article details.

    Upcoming Conferences, Financial Results, New Products, and Awareness Campaigns - Analyst Notes on Align Technology, LabCorp, Insulet, CareFusion, and DexCom

    PR Newswire – 9:20 AM ET 03/11/2014

    NEW YORK, March 11, 2014 Today, Analysts Review released its analysts' notes regarding Align Technology, Inc. (ALGN), Laboratory Corp. of America Holdings (LH), Insulet Corporation (PODD), CareFusion Corporation (CFN), and DexCom, Inc. (DXCM). Private wealth members receive these notes ahead of publication. Align Technology (ALGN), Inc. Analyst Notes.

  4. Show article details.

    Dexcom Supports NASCAR Driver Ryan Reed’s American Diabetes Association Drive to Stop Diabetes℠ Initiative

    Business Wire – 4:04 PM ET 03/05/2014

    Dexcom, Inc. (DXCM), the leader in continuous glucose monitoring, announced today it is supporting NASCAR driver Ryan Reed and the American Diabetes Association’s Drive to Stop Diabetes℠ national diabetes awareness initiative. “At the age of 17 I received the life-changing news that I had type 1 diabetes and was told I would never race again,” said Ryan Reed, NASCAR driver.

  5. Show article details.

    DexCom Announces Upcoming Conference Presentations

    Business Wire – 8:30 AM ET 02/25/2014

    DexCom, Inc. (DXCM) today announced that management will present an update on DexCom (DXCM) at the following upcoming investor conferences: The link to each webcast will be available on the DexCom (DXCM) website at www.dexcom.com by navigating to “About”, then “Investor Relations”, and then “Events and Webcasts”, and the presentations will be archived there for future reference.

  6. Show article details.

    DexCom, Inc. Reports Fourth Quarter and Full Year 2013 Financial Results

    Business Wire – 4:01 PM ET 02/20/2014

    DexCom, Inc. (DXCM) today reported its audited financial results as of and for the quarter and fiscal year ended December 31, 2013. For the full-year ended December 31, 2013, product revenue grew to $157.1 million, an increase of 69% from the $93.0 million in product revenue reported for 2012, and total revenue grew to $160.0 million, an increase of 60% from 2012.

  7. Show article details.

    DexCom Schedules Fourth Quarter and Full Year 2013 Earnings Release and Conference Call for February 20, 2014 at 4:30 p.m. Eastern Time

    Business Wire – 8:30 AM ET 02/06/2014

    DexCom, Inc. (DXCM) today announced that it plans to release its fourth quarter and full year 2013 financial results after market close on Thursday, February 20, 2014. To listen to the conference call, please dial 771-4371 or 585-4405 and use the confirmation number "36623521" approximately five minutes prior to the start time.

  8. Show article details.

    DexCom to Present at Leerink Global Healthcare Conference 2014

    Business Wire – 8:30 AM ET 02/06/2014

    DexCom, Inc. (DXCM) today announced that Steve Pacelli, Executive Vice President, Strategy and Corporate Development, will present an update on the company at the Leerink Global Healthcare Conference 2014 in New York, New York on Thursday, February 13, 2014 at 1:25pm.

  9. Show article details.

    Innovative Dexcom G4® PLATINUM Continuous Glucose Monitor (CGM) Receives FDA Approval for Use in Children Ages 2 to 17 Years

    Business Wire – 5:57 PM ET 02/03/2014

    Dexcom, Inc. (DXCM), the leader in continuous glucose monitoring, announced today that it has received U.S. Food and Drug Administration approval for its CGM device: Dexcom G4® PLATINUM for use in children ages 2 to 17 years with diabetes.

  10. Show article details.

    Dexcom, Inc. [DXCM] to Ring The NASDAQ Stock Market Opening Bell

    GlobeNewswire – 10:00 AM ET 12/11/2013

    What: Dexcom, Inc. (DXCM) [DXCM], a leader in glucose measurement and technology for people living with diabetes and healthcare providers, will visit the NASDAQ MarketSite in Times Square to celebrate a year of growth in large thanks to devoted patients and upcoming 2014 milestones. In honor of the occasion, CEO, Terry Gregg, will ring the Opening Bell. Dexcom (DXCM) has seen tremendous growth in 2013.

Page:

Today's and Upcoming Events

  • Apr
    30

    DXCM to announce Q1 earnings After Market (Unconfirmed)

Past Events (last 90 days)

  • Feb
    20

    DXCM Earnings Conference Call at 4:30 PM Listen

Data provided by Wall Street Horizon, Inc. © 2014

Technical Events

Technical Analysis

PROVIDED BY TRADING CENTRAL
As with all your investments through Fidelity, you must make your own determination whether an investment is appropriate for you. Fidelity is not recommending or endorsing this security by making it available to customers. You should conduct research and perform a thorough investigation as to the characteristics of any securities you intend to purchase. Before investing, you should read the prospectus, offering circular, indenture, or similar document carefully for a full description of the product, including its features and risks, to determine whether it is an appropriate investment for your investment objectives, risk tolerance, financial situation and other individual factors, and be sure to re-evaluate those factors on a periodic basis.

Performance data shown represents past performance, which is no guarantee of future results. Current performance may be higher or lower than the performance data quoted. Yield and return will vary, therefore, you may have a gain or loss when you sell your shares.


Stock markets are volatile and can decline significantly in response to adverse issuer, political, regulatory, market, or economic developments. Growth stocks can be more volatile than other types of stocks. Value stocks can continue to be undervalued by the market for long periods of time. Foreign securities are subject to interest-rate, currency-exchange-rate, economic, and political risks, all of which are magnified in emerging markets. Illiquidity is an inherent risk associated with investing in real estate and REITs. There is no guarantee the issuer of a REIT will maintain the secondary market for its shares and redemptions may be at a price which is more or less than the original price paid. Closed-end funds can trade at a discount to their NAV. Shareholders of Master Limited Partnerships may be treated as partners for tax purposes. Partnerships issue a Schedule K-1 (Form 1065) rather than a Form 1099 form for tax purposes. It lists the partner's share of income, deductions, credits, etc. Speak with your tax advisor to determine how this may affect you. A royalty trust is a type of corporation, mostly in the United States or Canada, usually involved in oil and gas production or mining. Royalty trusts may have special tax treatment, so you should consult a tax advisor on the potential tax consequences of investing in them.

News, commentary and events are from third-party sources unaffiliated with Fidelity. Fidelity does not endorse or adopt their content. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from their use.

Any data, charts and other information provided on this page are intended for research purposes to help self-directed investors evaluate many types of securities including, but not limited to common stocks, American Depository Receipts, Master Limited Partnerships, real estate investment trusts. traditional preferred stock, trust preferred securities, third-party trust certificates, convertible securities, mandatory convertible securities and other exchange-traded equity and/or debt securities. Criteria and inputs entered, including the choice to make security comparisons, are at the sole discretion of the user and are solely for the convenience of the user. Analyst opinions, ratings and reports are provided by third-parties unaffiliated with Fidelity. All information supplied or obtained from this page is for informational purposes only and should not be considered investment advice or guidance, an offer of or a solicitation of an offer to buy or sell a security, or a recommendation or endorsement by Fidelity of any security or investment strategy. Fidelity does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from its use.